|
WO2018026606A1
|
|
Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
|
|
AU2016282785A1
|
|
Aziridine containing DNA alkylating agents
|
|
CN107530556A
|
|
DNA alkylating agents
|
|
WO2015171647A1
|
|
Treatment of cancer
|
|
EP3024490A1
|
|
Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
|
|
US2016296538A1
|
|
Predictive and response biomarker for th-302 anti-cancer therapy
|
|
WO2013126539A1
|
|
Treatment of cancer
|
|
US2015005264A1
|
|
Predictive biomarker for hypoxia-activated prodrug therapy
|
|
EP2793899A1
|
|
Hypoxia activated prodrugs and mtor inhibitors for treating cancer
|
|
EP2793882A1
|
|
Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
|
|
KR20140045931A
|
|
Unit dose form for oral administration
|
|
KR20140038390A
|
|
Methods for treating cancer
|
|
KR20130045341A
|
|
Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
|
|
WO2012006032A2
|
|
Treatment of blood cancer
|
|
EP2443125A2
|
|
Camptothecin derivatives
|
|
EP2350664A1
|
|
Treatment of cancer using hypoxia activated prodrugs
|
|
WO2010019396A1
|
|
Administration of glufosfamide for the treatment of cancer
|
|
WO2009033165A1
|
|
Hypoxia activated prodrugs of bis-alkylating agents
|
|
WO2009018163A1
|
|
Hypoxia activated prodrugs of anthracyclines
|
|
WO2008151253A1
|
|
Hypoxia activated prodrugs of antineoplastic agents
|
